Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.

Abstract

BACKGROUND Epoetin therapy used to treat anemia among ESRD patients has cost Medicare ∼$40 billion. Since January 2011, epoetin has been reimbursed via a new bundled prospective payment system (PPS). Our aim was to determine changes in epoetin dosing and hematocrit levels in response to PPS by different types of dialysis providers. METHODS Data from the… (More)
DOI: 10.1159/000370334

Topics

  • Presentations referencing similar topics